These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26763586)

  • 21. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials.
    Saville BR; Berry DA; Berry NS; Viele K; Berry SM
    Clin Trials; 2022 Oct; 19(5):490-501. PubMed ID: 35993547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer.
    Douglas JE; Liu S; Ma J; Wolff RA; Pant S; Maitra A; Tamm EP; Bhosale P; Katz MHG; Varadhachary GR; Koay EJ
    BMC Cancer; 2022 Jan; 22(1):14. PubMed ID: 34980020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.
    Trippa L; Lee EQ; Wen PY; Batchelor TT; Cloughesy T; Parmigiani G; Alexander BM
    J Clin Oncol; 2012 Sep; 30(26):3258-63. PubMed ID: 22649140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Many-to-one comparisons after safety selection in multi-arm clinical trials.
    Hlavin G; Hampson LV; Koenig F
    PLoS One; 2017; 12(6):e0180131. PubMed ID: 28651023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
    Ursprung S; Mossop H; Gallagher FA; Sala E; Skells R; Sipple JAN; Mitchell TJ; Chhabra A; Fife K; Matakidou A; Young G; Walker A; Thomas MG; Ortuzar MC; Sullivan M; Protheroe A; Oades G; Venugopal B; Warren AY; Stone J; Eisen T; Wason J; Welsh SJ; Stewart GD
    BMC Cancer; 2021 Nov; 21(1):1238. PubMed ID: 34794412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II trials: a long-term investment with promising returns.
    Sharma MR; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
    Arjas E; Gasbarra D
    BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian basket trial design with false-discovery rate control.
    Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
    Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response adaptive randomization procedures in seamless phase II/III clinical trials.
    Zhu H; Piao J; Lee JJ; Hu F; Zhang L
    J Biopharm Stat; 2020; 30(1):3-17. PubMed ID: 31454295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Between-arm comparisons in randomized Phase II trials.
    Jung SH; George SL
    J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.
    Zabor EC; Kaizer AM; Garrett-Mayer E; Hobbs BP
    JCO Precis Oncol; 2022 Mar; 6():e2100390. PubMed ID: 35385345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian two-stage design for phase II oncology trials with binary endpoint.
    Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
    Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of clinical development pathways to advance tuberculosis regimen development.
    Chang V; Phillips PPJ; Imperial MZ; Nahid P; Savic RM
    BMC Infect Dis; 2022 Dec; 22(1):920. PubMed ID: 36494644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.